Align Summit 2026: Hiba Therapeutics is using AND-gating to try to make T-cell engagers safer and more effective for solid tumors
Founder & CEO Shariq Usmani describes the solid tumor problem that traditional T-cell engagers have faced and explains how Hiba's are designed to cleave only in the tumor microenvironment.
Coverage brought to you by










.png)